Home/Pipeline/Velexbru (tirabrutinib)

Velexbru (tirabrutinib)

B-cell malignancies

Phase 3Active

Key Facts

Indication

B-cell malignancies

Phase

Phase 3

Status

Active

Company

Ono Pharmaceutical

About Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd. is one of Japan's oldest and most established pharmaceutical companies with over 300 years of history. The company has evolved from traditional medicine to become a leader in oncology, particularly through its co-development of Opdivo with Bristol Myers Squibb, which has become one of the world's leading cancer immunotherapies. Ono maintains a strong focus on research and development with particular expertise in immunology, oncology, and CNS disorders, while expanding its presence in international markets.

View full company profile

Therapeutic Areas

Oncology Immunology Dermatology CNS Autoimmune

Other B-cell malignancies Drugs

Drug	Company	Phase	Status
Pirtobrutinib	Eli Lilly	Phase 3	Active
Mezagitamab	Kyowa Kirin	Phase 1/2	Active
KT-413	Kymera Therapeutics	Phase 1	Active
TG-1701	TG Therapeutics	Phase 1	Early-stage (based on general knowledge)
TG-1801	TG Therapeutics	Phase 1	Early-stage (based on general knowledge)
HMPL-760	HUTCHMED	Phase 1	Active
REC-3565	Recursion Pharmaceuticals	Phase 1	Active
UCART20x22	Cellectis	Phase 1/2	Active (in collaboration with Servier)
FT819	Fate Therapeutics	Phase 1	Active
Prulacabtagene leucel (prula-cel, ADI-001)	Adicet Bio	Phase 1	Previously Studied